Loading organizations...
§ Private Profile · Vancouver, BC, Canada
Biotechnology company developing living human tissue therapeutics using 3D bioprinting for drug discovery and regenerative medicine.
Aspect Biosystems is a Vancouver, British Columbia-based biotechnology company that develops a proprietary microfluidic 3D bioprinting platform to create living human tissue therapeutics for regenerative medicine and drug discovery. The organization utilizes its Lab-on-a-Printer technology to produce bioprinted tissues designed to replace, repair, or supplement biological functions for patients with complex conditions like diabetes and liver disorders. The company advances its internal pipeline and collaborates with major pharmaceutical firms, highlighted by a 2023 strategic partnership with Novo Nordisk that included $73 million in initial payments and up to $2.6 billion in potential milestone royalties. The enterprise previously secured a $20 million Series A financing round in 2020 led by Radical Ventures, with additional participation from Pangaea Ventures and Rhino Ventures. Aspect Biosystems was founded in 2013 by Tamer Mohamed, Konrad Walus, Sam Wadsworth, and Simon Beyer.
Aspect Biosystems has raised $215.4M across 4 funding rounds.
Aspect Biosystems has raised $215.4M in total across 4 funding rounds.
Aspect Biosystems has raised $215.4M in total across 4 funding rounds.
Aspect Biosystems's investors include Dimension Capital, Kevin Hartz, Accel, Felicis Ventures, Sequoia Capital, Government of British Columbia, Government of Canada, Radical Ventures, Brightspark Ventures, Freestyle Capital, FTX Ventures, Jump Crypto.
Aspect Biosystems has raised $215.4M across 4 funding rounds. Most recently, it raised $120.0M Series B in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2025 | $120M Series B | Dimension Capital | Kevin Hartz, Accel, Felicis Ventures, Sequoia Capital | Announced |
| Jul 10, 2024 | $72.8M Venture Round | Government OF British Columbia, Government OF Canada | — | Announced |
| Jan 1, 2020 | $20M Series A | Radical Ventures | Brightspark Ventures, Freestyle Capital, FTX Ventures, Jump Crypto | Announced |
| Nov 15, 2018 | $2.7M Venture Round | Government OF Canada | — | Announced |
Aspect Biosystems is a biotechnology company developing a full-stack tissue therapeutic platform that uses proprietary AI-powered bioprinting to create implantable bioprinted tissue therapeutics (BTTs). These BTTs replace, repair, or supplement lost biological functions, targeting metabolic and endocrine diseases like type 1 diabetes, primary adrenal insufficiency, and acute liver failure.[1][2][3][4][8] The platform serves patients with incurable diseases and partners with pharma giants like Novo Nordisk, addressing root causes without chronic immunosuppression or full organ transplants.[1][3][6] Growth momentum includes a major 2023 partnership with Novo Nordisk—yielding $75M upfront and up to $650M in milestones—plus investments from Radical Ventures and Dimension Capital, advancing an internal pipeline from preclinical stages.[1][5][6]
Aspect Biosystems spun out from engineering and medicine research groups at the University of British Columbia, evolving from initial 3D bioprinting for drug testing models into a comprehensive regenerative medicine platform.[7] Founders leveraged expertise in microfluidics and tissue engineering to pioneer on-demand human tissue creation, starting with customizable 3D models for pharma research before shifting to therapeutics.[5][7] Early traction came from partnerships with academic and biopharma entities, culminating in high-profile deals like Novo Nordisk for diabetes and obesity treatments, marking a pivot to clinical-stage products.[1][3][6][7]
Aspect's platform stands out through integrated, end-to-end capabilities beyond basic bioprinting:
Aspect rides the regenerative medicine wave, merging bioprinting, AI, and stem cells to pioneer BTTs amid rising demand for cell therapies beyond traditional transplants.[1][2][7] Timing aligns with advances in stem cell differentiation and biomanufacturing, fueled by pharma's push for functional cures in chronic diseases affecting millions (e.g., diabetes).[3][6] Market forces like Novo Nordisk's scale and investor interest from Radical Ventures favor Aspect, enabling rapid clinic progression while reducing organ shortage risks.[1][5][6] It influences the ecosystem by enabling precise drug testing models and novel therapeutics, potentially reshaping personalized medicine and accelerating shelved drug revivals.[7]
Aspect is poised to advance its preclinical pipeline into clinical trials, prioritizing diabetes/obesity via Novo Nordisk and internal programs for liver/adrenal disorders, with potential first-in-human data soon.[6][8] Trends like AI-optimized biomanufacturing and allogeneic cell therapies will amplify its edge, expanding to more endocrine indications amid growing regenerative investment.[1][4][5] Its influence may evolve from platform innovator to category leader, transforming incurable disease treatment—building on its UBC roots to deliver the functional cures that redefine biotech.